Literature DB >> 6104322

Prenatal diagnosis of metachromatic leukodystrophy in a family with pseudo arylsulfatase A deficiency by the cerebroside sulfate loading test.

H Kihara, C K Ho, A L Fluharty, K K Tsay, P L Hartlage.   

Abstract

Prenatal diagnosis was requested by a family at risk for metachromatic leukodystrophy (MLD). An examination of the family leukocyte arylsulfatase A profile revealed that the mother had pseudo arylsulfatase A deficiency. Cultured amniotic fluid cells were deficient in arylsulfatase A, so two possibilities were indicated: the fetus was affected with MLD or had the pseudodeficiency phenotype. The only known biochemical test to differentiate the two enzyme deficient phenotypes is cerebroside sulfate loading of growing fibroblasts. The pseudodeficient cells hydrolyze the incorporated sulfatide as efficiently as control cells, whereas MLD cells show no hydrolysis. Application of this test to the at risk cultured amniotic fluid cells resulted in appreciable uptake of the sulfolipid, but no hydrolysis. Control amniotic fluid cell cultures hydrolyzed 82 to 95% of the incorporated sulfatide. Therefore, an affected fetus was indicated. Fibroblasts derived from the aborted fetus showed a deficiency of arylsulfatase A and a similar inability to hydrolyze cerebroside sulfate in the loading test. The loading technique allowed the prenatal diagnosis of MLD when the arylsulfatase A analysis was equivocal.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6104322     DOI: 10.1203/00006450-198003000-00009

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  28 in total

1.  Quantitative correlation between the residual activity of beta-hexosaminidase A and arylsulfatase A and the severity of the resulting lysosomal storage disease.

Authors:  P Leinekugel; S Michel; E Conzelmann; K Sandhoff
Journal:  Hum Genet       Date:  1992-03       Impact factor: 4.132

2.  Direct tandem mass spectrometric profiling of sulfatides in dry urinary samples for screening of metachromatic leukodystrophy.

Authors:  Ladislav Kuchař; Befekadu Asfaw; Helena Poupětová; Jitka Honzíková; František Tureček; Jana Ledvinová
Journal:  Clin Chim Acta       Date:  2013-07-06       Impact factor: 3.786

3.  Late-onset Krabbe disease initially diagnosed as cerebroside sulfatase activator deficiency.

Authors:  A L Fluharty; L Neidengard; D Holtzman; H Kihara
Journal:  Metab Brain Dis       Date:  1986-09       Impact factor: 3.584

4.  Myoclonic epilepsy of Lafora and arylsulphatase A deficiency in the same patient.

Authors:  B Bertagnolio; F Girotti; D Pelucchetti; M Pandolfo
Journal:  J Inherit Metab Dis       Date:  1989       Impact factor: 4.982

5.  Placental steroid deficiency: association with arylsulfatase A deficiency.

Authors:  J Vidgoff; M M Buxman; L J Shapiro; R L Dimond; T G Wilson; C A Hepburn; T Tabei; W R Heinrichs
Journal:  Am J Hum Genet       Date:  1982-05       Impact factor: 11.025

6.  The genetics of the aryl sulfatase A locus.

Authors:  T Schaap; J Zlotogora; E Elian; Y Barak; G Bach
Journal:  Am J Hum Genet       Date:  1981-07       Impact factor: 11.025

7.  Cerebroside sulfatase activator deficiency induced metachromatic leukodystrophy.

Authors:  R L Stevens; A L Fluharty; H Kihara; M M Kaback; L J Shapiro; B Marsh; K Sandhoff; G Fischer
Journal:  Am J Hum Genet       Date:  1981-11       Impact factor: 11.025

8.  Compound heterozygosity for metachromatic leukodystrophy and arylsulfatase A pseudodeficiency alleles is not associated with progressive neurological disease.

Authors:  J M Penzien; J Kappler; N Herschkowitz; B Schuknecht; P Leinekugel; P Propping; T Tønnesen; H Lou; H Moser; S Zierz
Journal:  Am J Hum Genet       Date:  1993-03       Impact factor: 11.025

9.  Biliary disease in metachromatic leukodystrophy.

Authors:  L Heier; A Daneman; J A Lowden; E Cutz; S Craw; D J Martin
Journal:  Pediatr Radiol       Date:  1983

10.  Arylsulfatase A in pseudodeficiency.

Authors:  B Herz; G Bach
Journal:  Hum Genet       Date:  1984       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.